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(http://creativecommoheimer’s disease. Individuals with DS are therefore an important population for randomized
controlled trials to prevent or delay cognitive decline, though it is essential to understand the time
course of early cognitive changes.
Methods: We conducted the largest cognitive study to date with 312 adults with DS to assess age-
related and Alzheimer’s disease–related cognitive changes during progression from preclinical to
prodromal dementia, and prodromal to clinical dementia.
Results: Changes in memory and attention measures were most sensitive to early decline. Resulting
sample size calculations for randomized controlled trials to detect significant treatment effects to
delay decline were modest.
Discussion: Our findings address uncertainties around the development of randomized controlled tri-
als to delay cognitive decline in DS. Such trials are essential to reduce the high burden of dementia in
people with DS and could serve as proof-of-principle trials for some drug targets.
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Down syndrome (DS), caused by trisomy of chromosome
21, has a UK incidence of approximately one in 1000 live
births [1] and is associated with intellectual disability (ID)
and an ultra-high risk of developing Alzheimer’s disease
(AD) [2]. The cumulative incidence of dementia has been
suggested to be 95.7% by the age of 68 years with a mean
age of diagnosis of 55 years [3], indicating cognitive decline
is a near universal part of aging in DS. This increased de-ny conflicts of interest.
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he Authors. Published by Elsevier Inc. on behalf of the Alzh
ns.org/licenses/by/4.0/).mentia risk is driven by the overexpression of genes on chro-
mosome 21, in particular the amyloid precursor protein
(APP) gene; deposits of its protein product, amyloid-b, are
a characteristic feature of AD and are found in the brains
of adults with full trisomy 21 by the mid-30s [2,4]. DS
may therefore be viewed as a genetic cause of AD
alongside known autosomal dominant pathogenic
mutations in the APP, presenilin-1 (PSEN1), and
presenilin-2 (PSEN2) genes (autosomal dominant AD
[ADAD]) [5], although the clinical course during the early
stages of AD in DS is less well described [6].
Understanding the time course of AD in DS is essential to
improving detection and monitoring of decline and will aideimer’s Association. This is an open access article under the CC BY license
Table 1
Summary of assessments used
Domain Test name Primary ability assessed Description Outcomes and score ranges
IQ Kaufmann Brief Intelligence Test 2
(KBIT-2) [9]
General cognitive
abilities
Subtests assess participants’ verbal
abilities (verbal knowledge and
riddles) and nonverbal abilities
(matrices).
Verbal raw score (0–108); Nonverbal
raw score (0–46)
Memory CANTAB paired associates learning
(PAL) [10]
Visuospatial associate
memory
Participants were required to
remember locations of an
increasing number of patterns
hidden behind boxes on a
computer screen.
First trial memory score (0–26);
Number of stages completed (0–8)
CAMCOG orientation [11] Orientation Assesses participants’ knowledge of
when it is and where they are.
Total score (0–12)
Object memory test [12] Recall memory Participants were required to name
and remember a series of objects,
then recall them in two immediate
trials and one 5-minute delayed
trial.
Immediate recall (0–14); Delayed
recall (0–7)
Dementia Questionnaire for People
with Learning Disabilities (DLD)
[13]
Memory and orientation Informants answer 22 questions about
abilities associated with cognitive
decline over the last 2 months.
Cognitive abilities (0–44)
Observer Memory Questionnaire
(OMQ) [14]
Memory Informants answer 30 questions about
individuals’ memory abilities over
the last 2 months.
Total score (30–150)
Executive
function
CANTAB intra-/extra-dimensional
set shift (IED) [10]
Rule learning and set
shifting
Participants were required to learn
rules about which was the
“correct” of two presented patterns
on a computer screen, with a rule
change after 6 consecutive correct
trials.
Number of stage 1 errors (0–50);
Number of stages completed (0–9)
Verbal fluency [15] Verbal fluency Participants were asked to name as
many animals as possible in 1
minute.
Number of unique animals (0–N/A)
Tower of London [16,17] Working memory
and planning
Participants were required to move
beads on a board to match
presented configurations.
Total score (0–10)
Behavior Rating Inventory of
Executive Function–Adult version
(BRIEF-A) [18]
Executive function Informants answer 70 questions about
problems with behaviors relating
to executive functioning over the
last month.
Total score (70–210); Behavioral
Regulation Index (30–90);
Metacognition Index (40–120)
Attention CANTAB simple reaction time (SRT)
[10,19]
Attention/motor abilities Participants were required to press a
button as soon as a white square
appeared on a computer screen.
Total number of correct responses (0–
100);Mean latency (N/A); Latency
standard deviation (N/A)
Motor Finger-nose pointing [20] Motor coordination Participants alternatively touch their
nose and a red circle 45 cm away
for 20 seconds.
Total number of times the circle is
touched (0–N/A)
Developmental NEuroPSYchological
Assessment-II (NEPSY-II)
visuomotor precision [21]
Hand-eye coordination Participants were timed as they traced
around train, car, and motorbike
tracks, with time and number of
errors for each track used to
determine overall scores.
Train and car score (0–30); Car and
motorbike score (0–52)
Adaptive Short Adaptive Behavior Scale (short
ABS) [22]
Adaptive abilities Informants answer 24 questions about
everyday adaptive abilities.
Total score (0–113); Personal self-
sufficiency (0–33); Community
self-sufficiency (0–48); Personal-
social responsibility (0–32)
Dementia Questionnaire for People
with Learning Disabilities (DLD)
[13]
Adaptive abilities Informants answer 28 questions about
behaviors associated with
cognitive decline over the last 2
months.
Social abilities (0–60)
C.M. Startin et al. / Alzheimer’s & Dementia- (2018) 1-132in designing intervention studies [7]. Given their AD burden,
individuals with DS are an important population for clinical
trials of treatments to prevent or modify AD, particularly fordrugs targeting amyloid overproduction or deposition. We
therefore aimed to understand neuropsychological changes
across the time course of AD development at a population
C.M. Startin et al. / Alzheimer’s & Dementia- (2018) 1-13 3level in adults with DS using data from a large, ongoing, in-
depth phenotyping study of the development of AD in DS
[8]. We aimed to estimate the effect of the apolipoprotein
E (APOE) ε4 allele, the best known genetic risk factor for
AD aside from variations in APP, PSEN1, and PSEN2, on
performance for outcomes most sensitive to cognitive
changes. Using such outcomes as hypothetical clinical trial
primary outcomes, we also aimed to estimate sample sizes
for randomized controlled trials (RCTs) to delay cognitive
decline either 10–15 years before the mean age of dementia
diagnosis or alternatively around the mean age of diagnosis.2. Methods
2.1. Participants
We recruited 312 individuals with a clinical diagnosis of
DS aged 161 years across England and Wales. Full details
regarding participants and the assessment can be found in
the study by Startin et al. [8].
Ethical approval was obtained from the NorthWestWales
Research Ethics Committee (13/WA/0194). Where individ-
uals had capacity to consent for themselves, we obtained
written informed consent. Where individuals did not have
capacity to consent, a consultee was asked to approve the in-
dividual’s inclusion based on their knowledge of the individ-
ual and his/her wishes, in accordance with the UK Mental
Capacity Act 2005.
2.2. Genetic analysis
DS was confirmed genetically in 299 individuals using
saliva or blood samples. The APOE genotype was deter-
mined using a Thermo Fisher Scientific TaqMan assay for
SNPs rs7412 and rs429358 (Waltham, MA).
2.3. Assessment
Our assessment battery (Table 1) included cognitive tests
completed with individuals who were able to engage in
assessment and who met vision and hearing screening
thresholds, and informant ratings from relatives or paid
carers who knew the individual well for all participants
[8]. Informant measures are important for adults who cannot
engage in cognitive assessments, who have vision or hearing
difficulties, or who are at floor on cognitive tests. Our battery
has previously been validated and adapted for use in older
adults with DS, including those with little verbal ability
[8,23], and focuses on abilities related to memory,
executive function, and motor coordination, as these are
often impaired in DS [19] and further impaired by dementia
[23].
2.3.1. Missing data
Some adults, in particular those with dementia, had diffi-
culty engaging in cognitive tests [8]. Excluding such adults
could bias analyses. We therefore imputed scores (seeSupplementary Table 1; total 14.1% of scores) as follows: in-
dividuals who were clearly unable to understand task in-
structions were allocated a score of zero where appropriate
and when not appropriate were allocated a score to indicate
poor performance. For IED stage 1 errors, a score of 25 was
given (representing performance by chance). For SRT total
correct, the minimum obtained score in our sample was
given, whereas for SRT mean latency and SRT latency stan-
dard deviation, the maximum obtained scores in our sample
were given (representing the poorest performance
observed); these values were 13, 2500.61 ms, and
980.98 ms, respectively. Finally, when the KBIT-2 riddles
subtest was incomplete, this score was imputed based on
the linear relationship between the riddles and verbal knowl-
edge subtest scores in our sample (r5 0.869, P, .001), and
the KBIT-2 verbal raw score was calculated using this
imputed score.
Missing items from the Dementia Questionnaire for Peo-
ple with Learning Disabilities (DLD), Observer Memory
Questionnaire (OMQ), and Behavior Rating Inventory of
Executive Function–Adult version (BRIEF-A) were imputed
for up to 15% of items within each domain with the nearest
integer to the mean value of completed scores. Questionnaire
domains containing more than 15% of missing items were
excluded from analyses.2.4. Statistical analysis
SPSS, version 22, was used for analyses. Age and demo-
graphic factors were compared between groups using
two-sample t-tests and c2 tests, respectively. To account
for multiple comparisons, P , .01 was used to determine
statistical significance.
2.4.1. Earliest cognitive markers of AD-related
neuropathology
Because virtually all individuals with DS develop AD
neuropathology as they age, we hypothesized that age-
associated differences in outcome measures would be
related to the progression of AD pathology, and this effect
can be used to identify the earliest markers of cognitive
decline. Based on the presence of amyloid neuropathology
by the mid-30s [2,4], performance of participants aged 16-
30 years therefore represents abilities before the
development of significant AD neuropathology and
subsequent cognitive decline. We compared individuals’
performance regardless of dementia status in 5-year age
bands (31–35, 36–40, 41–45, 46–50, 51–55, and 56–
60 years) against those aged 16–30 years using ANCOVAs,
with premorbid ID severity and a measure of multimorbidity
(presence of two or more common health conditions [24]
excluding dementia and epilepsy developed after the age
of 35 years) included as covariates to adjust for potential
confounding effects. h2 values determined the overall
effect size of age group. Pairwise comparisons with Bonfer-
roni corrections determined age groups for whom
C.M. Startin et al. / Alzheimer’s & Dementia- (2018) 1-134performance was significantly poorer than that of those aged
16–30 years.
2.4.2. Markers associated with clinical stage of AD
Preclinical (asymptomatic) AD can be defined as the
stage when biomarker changes are present, but clinical
symptoms have not yet developed, whereas prodromal AD
is usually defined as the earliest symptomatic stage when
cognitive symptoms are present, but the threshold for de-
mentia diagnosis has not yet been reached [25]. Owing to
postmortem studies indicating amyloid neuropathology in
DS by the mid-30s [2,4], we considered those aged
361 years with no clinical symptoms of dementia to be in
a preclinical state, and those with cognitive symptoms but
no clinical diagnosis of dementia in a prodromal state. For
participants aged 361 years with no clinical dementia
diagnosis, two ID psychiatrists independently reviewed
detailed information on dementia symptoms using the
Cambridge Examination of Mental Disorders of Older
People with Down’s syndrome and others with Intellectual
Disabilities (CAMDEX-DS) [26] with diagnostic rating pro-
cedures described previously [27]. A consensus decision
was made to allocate those with cognitive symptoms associ-
ated with AD but no evidence of decline in functional abil-
ities and no other significant cause of decline to a
prodromal dementia group, and asymptomatic individuals
to a preclinical group. We then compared performance for
adults aged 361 years in a preclinical state to those in a pro-
dromal state, and that of those in a prodromal state to those
with a clinical diagnosis of dementia using ANCOVAs to
identify markers of AD progression while controlling for
age, premorbid ID severity, and multimorbidity, with h2
values to estimate the effect size of group.
2.4.3. Sensitivity of cognitive markers to APOE genotype
To determine the effect of an APOE ε4 allele on perfor-
mance for selected outcomes that were most sensitive to
cognitive changes in adults aged 361 years, we compared
performance for those with genotype APOE ε3/ε3 and
APOE ε3/ε4 using ANCOVAs while controlling for age, pre-
morbid ID severity, and multimorbidity, with values of h2 to
estimate the effect size of genotype.
2.4.4. Sample sizes for RCTs using cognitive markers
We estimated sample sizes for two hypothetical disease-
modifying RCTs using our participant sample and potential
primary outcome measures, with the aim to delay individ-
uals’ abilities declining. Both trials were hypothesized to
last 5 years, with the aim to prevent performance of adults
aged 36–40 years declining to that of adults aged 41–45 years
(i.e., delaying early decline) or to prevent performance of
adults aged 46–50 years declining to that of adults aged
51–55 years (i.e., delaying later decline). Mean scores for
the two relevant age groups were used to determine expectedgroup differences (excluding individuals with clinical de-
mentia in the younger age group as these individuals would
be ineligible for such a trial), and expected group differences
used with the associated pooled standard deviation (SD) to
estimate the potential sample sizes needed for RCTs with
P, .05 and 90% power. Owing to small sample sizes result-
ing in large confidence intervals for mean group differences,
sample sizes were also estimated using the midpoint be-
tween mean group differences and their lower 95% confi-
dence interval as a more cautious estimate for expected
group differences. All sample size estimates were
calculated by
n52F
s
d
2
where n is the sample size needed per group, F is 10.51
(based on P , .05 and 90% power), s is the pooled SD,
and d is the expected group difference.3. Results
3.1. Earliest cognitive markers of AD-related
neuropathology
Demographic information and scores for each outcome
measure for 297 individuals aged 16-60 years split into
age groups can be seen in Table 2; adults aged 611 years
(n5 15) were excluded due to small samples. All outcomes
aside from BRIEF-A scores had a significant (P , .001)
overall relationship with age group, with poorer perfor-
mance in older age groups (see Fig. 1 for an example).
Age group showed the greatest effect size as determined us-
ing h2 values for measures from the paired associates
learning (PAL), object memory, SRT, and Developmental
NEuroPSYchological Assessment-II explaining more than
30% of variance in scores for each outcome (Table 2).
Comparing the older age groups with those aged 16-
30 years (Table 3 and Supplementary Table 2), the earliest
changes in performance were seen for the PAL first trial
memory score and SRT latency SD, with significantly poorer
performance starting in adults aged 41-45 years (P 5 .002
and P 5 .001, respectively). Performance for the majority
of other outcomes became significantly poorer for adults
aged 46–50 years, with the exception of several informant-
rated adaptive ability scores and BRIEF-A scores. By 51–
55 years, all measures except BRIEF-A scores showed
significantly poorer performance.3.2. Markers associated with clinical stage of AD
Ages and scores for each outcome measure for 170 adults
aged 361 years split into preclinical, prodromal, and clinical
dementia groups can be seen in Table 4, with results of group
comparisons in Table 4 and Table 5 and an example of group
Table 2
Demographic information and scores for each outcome for participants split by age group, with the overall effect of comparing all age groups
Demographics and outcomes 16–30 years 31–35 years 36–40 years 41–45 years 46–50 years 51–55 years 56–60 years Age group comparison
Total number 94 30 27 24 52 42 28 N/A
Number failed hearing or vision test 2 (2.1%) 1 (3.3%) 2 (7.4%) 1 (4.2%) 2 (3.8%) 6 (14.3%) 1 (3.6%) N/A
Age (years) 22.89 6 4.11 32.60 6 1.30 38.00 6 1.44 43.17 6 1.31 47.92 6 1.31 52.83 6 1.46 57.75 6 1.40 N/A
Sex
Male 46 (48.9%) 13 (43.3%) 14 (51.9%) 16 (66.7%) 30 (57.7%) 19 (45.2%) 11 (39.3%) X(6) 5 6.17, P 5 .404
Female 48 (51.1%) 17 (56.7%) 13 (48.1%) 8 (33.3%) 22 (42.3%) 23 (54.8%) 17 (60.7%)
Premorbid ID severity*
Mild 33 (35.1%) 14 (46.7%) 10 (37.0%) 11 (45.8%) 26 (50.0%) 12 (28.6%) 8 (28.6%) X(12) 5 19.66, P 5 .074
Moderate 48 (51.1%) 16 (53.3%) 13 (48.1%) 9 (37.5%) 17 (32.7%) 17 (40.5%) 15 (53.6%)
Severe 13 (13.8%) 0 (0.0%) 4 (14.8%) 4 (16.7%) 9 (17.3%) 13 (31.0%) 5 (17.9%)
Ethnicity
White 77 (81.9%) 24 (80.0%) 23 (85.2%) 21 (87.5%) 44 (84.6%) 38 (90.5%) 26 (92.9%) X(6) 5 3.79, P 5 .705
Nonwhite 17 (18.1%) 6 (20.0%) 4 (14.8%) 3 (12.5%) 8 (15.4%) 4 (9.5%) 2 (7.1%)
Multimorbidity; number with two
or more health conditions
63 (67.0%) 16 (53.3%) 17 (63.0%) 15 (62.5%) 32 (61.5%) 22 (52.4%) 13 (46.4%) X(6) 5 5.86, P 5 .439
Dementia statusy
Preclinical N/A N/A 16 (76.2%) 13 (56.5%) 25 (53.2%) 11 (29.7%) 1 (3.7%) N/A
Prodromal N/A N/A 2 (9.5%) 8 (34.8%) 12 (25.5%) 10 (27.0%) 12 (44.4%)
Clinical N/A N/A 3 (14.3%) 2 (8.7%) 10 (21.3%) 16 (43.2%) 14 (51.9%)
Missing N/A N/A 6 1 5 5 1
APOE genotypey
ε2/ε2 0 (0.0%) 1 (3.4%) 1 (3.7%) 0 (0.0%) 1 (2.0%) 0 (0.0%) 1 (3.7%) N/A
ε2/ε3 13 (14.3%) 6 (20.7%) 3 (11.1%) 3 (13.6%) 4 (8.0%) 3 (7.9%) 5 (18.5%)
ε3/ε3 50 (54.9%) 16 (55.2%) 16 (59.3%) 12 (54.5%) 31 (62.0%) 25 (65.8%) 15 (55.5%)
ε3/ε4 24 (26.4%) 6 (20.7%) 7 (25.9%) 7 (31.8%) 11 (22.0%) 9 (23.7%) 5 (18.5%)
ε4/ε4 3 (3.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.6%) 0 (0.0%)
ε2/ε4 1 (1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (6.0%) 0 (0.0%) 1 (3.7%)
Missing 3 1 0 2 2 4 1
KBIT-2 verbal raw score 33.76 6 17.03 38.07 6 16.32 32.92 6 17.08 31.39 6 18.74 24.56 6 19.16 17.36 6 16.33 10.19 6 14.36 F(6,273) 5 12.57,
P , .001, h2 5 0.216
KBIT-2 nonverbal raw score 15.08 6 7.41 14.69 6 5.02 14.26 6 7.90 12.32 6 7.07 10.13 6 7.07 8.54 6 6.81 3.88 6 5.57 F(6,265) 5 14.69,
P , .001, h2 5 0.250
PAL first trial memory score 10.50 6 5.83 9.00 6 5.31 9.32 6 7.10 5.90 6 5.97 5.02 6 5.46 2.32 6 3.82 1.36 6 2.29 F(6,240) 5 17.23,
P , .001, h2 5 0.301
PAL stages completed 6.32 6 2.68 5.96 6 2.14 5.50 6 3.17 4.57 6 3.14 3.59 6 2.92 2.16 6 2.52 1.60 6 2.25 F(6,240) 5 19.21,
P , .001, h2 5 0.324
Orientation 9.34 6 3.77 10.24 6 2.76 9.17 6 4.03 7.62 6 4.21 7.11 6 4.77 5.69 6 4.79 2.58 6 3.50 F(6,257) 5 14.36,
P , .001, h2 5 0.251
Object memory immediate recall 10.16 6 3.29 10.52 6 1.92 8.77 6 3.90 8.60 6 4.11 7.83 6 4.64 4.65 6 4.47 2.32 6 3.66 F(6,248) 5 21.82,
P , .001, h2 5 0.346
Object memory delayed recall 5.68 6 1.65 6.10 6 1.05 4.86 6 2.17 4.50 6 2.31 4.43 6 2.60 2.62 6 2.59 1.36 6 2.00 F(6,248) 5 22.42,
P , .001, h2 5 0.352
DLD cognitive scorez 8.22 6 8.68 5.50 6 7.01 7.83 6 9.50 13.52 6 12.37 15.60 6 12.81 21.52 6 12.09 23.38 6 10.54 F(6,252) 5 16.09,
P , .001, h2 5 0.277
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Table 2
Demographic information and scores for each outcome for participants split by age group, with the overall effect of comparing all age groups (Continued )
Demographics and outcomes 16–30 years 31–35 years 36–40 years 41–45 years 46–50 years 51–55 years 56–60 years Age group comparison
OMQ total scorez 76.87 6 18.15 68.17 6 18.08 80.58 6 22.51 81.21 6 19.42 89.05 6 23.87 95.41 6 21.95 103.35 6 18.02 F(6,244) 5 10.25,
P , .001, h2 5 0.201
IED stage 1 errorsz 4.18 6 6.99 5.04 6 8.70 6.64 6 10.03 11.05 6 11.57 10.71 6 12.34 13.21 6 10.64 20.21 6 10.28 F(6,242) 5 12.03,
P , .001, h2 5 0.230
IED stages completed 6.52 6 2.54 6.46 6 2.83 6.05 6 3.36 4.95 6 3.38 4.64 6 3.76 2.91 6 3.34 1.08 6 2.39 F(6,242) 5 14.56,
P , .001, h2 5 0.265
Verbal fluency 10.92 6 6.08 10.52 6 5.35 9.74 6 6.59 8.14 6 5.43 6.65 6 6.25 4.54 6 5.05 2.19 6 3.66 F(6,260) 5 12.01,
P , .001, h2 5 0.217
Tower of London 7.22 6 3.04 7.36 6 3.34 7.00 6 3.57 5.91 6 3.68 4.57 6 3.88 3.00 6 3.66 2.35 6 3.57 F(6,258) 5 13.67,
P , .001, h2 5 0.241
BRIEF-A total scorez 123.14 6 25.59 115.04 6 27.80 119.91 6 23.04 122.53 6 22.83 128.61 6 29.25 131.11 6 29.84 135.76 6 30.16 F(6,230) 5 1.47,
P 5 .188, h2 5 0.037
BRIEF-A Behavioral
Regulation Indexz
51.11 6 11.81 49.55 6 13.85 50.62 6 10.77 50.85 6 10.25 54.80 6 12.84 52.45 6 12.77 55.11 6 12.73 F(6,250) 5 1.13,
P 5 .344, h2 5 0.026
BRIEF-A Metacognition Indexz 72.23 6 16.70 66.46 6 16.79 69.64 6 14.97 72.16 6 14.37 75.13 6 18.25 78.36 6 19.39 80.24 6 18.11 F(6,231) 5 1.58,
P 5 .154, h2 5 0.039
SRT total correct 91.60 6 16.20 93.67 6 12.11 80.00 6 31.11 81.47 6 27.05 70.44 6 34.31 52.06 6 35.95 37.48 6 33.85 F(6,232) 5 20.54,
P , .001, h2 5 0.347
SRT mean latencyz 692.50 6 459.80 767.75 6 526.72 1041.84 6 778.43 1154.79 6 553.89 1274.22 6 764.30 1738.96 6 763.32 2017.53 6 713.45 F(6,232) 5 21.84,
P , .001, h2 5 0.361
SRT latency standard deviationz 323.48 6 229.30 317.83 6 174.02 426.61 6 296.51 536.88 6 217.02 568.74 6 295.18 733.28 6 259.83 807.48 6 244.49 F(6,232) 5 23.42,
P , .001, h2 5 0.377
Finger-nose pointing 10.99 6 5.46 10.69 6 4.70 8.83 6 5.95 7.48 6 5.11 6.59 6 5.25 5.60 6 5.93 2.73 6 3.86 F(6,260) 5 13.72,
P , .001, h2 5 0.241
NEPSY-II train and car 15.83 6 5.24 16.10 6 5.43 15.00 6 5.48 14.43 6 6.45 8.98 6 7.65 8.68 6 7.94 4.77 6 6.48 F(6,259) 5 18.56,
P , .001, h2 5 0.301
NEPSY-II car and motorbike 16.73 6 9.32 17.83 6 10.58 15.45 6 9.05 12.14 6 9.57 6.81 6 8.49 6.06 6 7.56 2.92 6 4.77 F(6,259) 5 17.89,
P , .001, h2 5 0.293
Short ABS total score 76.72 6 19.88 85.76 6 17.68 76.75 6 23.65 73.95 6 26.21 68.13 6 25.39 54.64 6 27.56 50.17 6 25.00 F(6,260) 5 9.97,
P , .001, h2 5 0.187
Short ABS personal
self-sufficiency
28.63 6 4.70 29.79 6 3.90 27.84 6 5.60 26.86 6 5.12 25.89 6 7.45 21.58 6 9.40 20.42 6 9.30 F(6,266) 5 10.17,
P , .001, h2 5 0.187
Short ABS community
self-sufficiency
26.67 6 10.28 31.24 6 10.05 27.76 6 11.51 25.70 6 14.32 22.74 6 12.23 17.64 6 11.97 14.04 6 10.44 F(6,264) 5 9.08,
P , .001, h2 5 0.171
Short ABS personal-social
responsibility
21.78 6 6.60 24.72 6 5.61 20.96 6 7.70 21.52 6 7.96 19.70 6 7.70 16.32 6 7.72 16.20 6 7.22 F(6,265) 5 5.27,
P , .001, h2 5 0.107
DLD social scorez 9.77 6 6.76 7.86 6 6.90 10.28 6 7.48 11.24 6 7.46 13.52 6 10.04 17.91 6 12.05 22.36 6 11.50 F(6,259) 5 11.16,
P , .001, h2 5 0.205
NOTE. Ages and scores given are mean 6 standard deviation. Group comparisons included premorbid ID severity and multimorbidity as covariates.
Abbreviations: ABS, Adaptive Behavior Scale; BRIEF-A, Behavior Rating Inventory of Executive Function–Adult version; DLD, Dementia Questionnaire for Peoplewith Learning Disabilities; ID, intellectual
disability; IED, intra-/extra-dimensional set shift; KBIT-2, Kaufmann Brief Intelligence Test 2; NEPSY-II, Developmental NEuroPSYchological Assessment-II; OMQ, Observer Memory Questionnaire; PAL,
paired associates learning; SRT, simple reaction time.
*Assessed via carer report based on everyday functional descriptions.
yPercentages calculated excluding missing values.
zHigher scores represent poorer ability.
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Fig. 1. Mean PAL first trial memory scores for (A) different age groups and (B) preclinical, prodromal, and clinical dementia groups (error bars represent 95%
confidence intervals).
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(n 5 8) or when decline was potentially due to another
cause such as depression (n 5 10) were excluded from ana-
lyses.
Adults with prodromal dementia performed significantly
poorer than thosewith preclinical dementia for several mem-
ory, executive function, and attention outcomes. The largest
effect sizes were found for the PAL first trial memory score,
SRT latency SD, OMQ score, and BRIEF-A Metacognition
Index, where group accounted for more than 12% of vari-
ance in scores for each outcome.
Adults with clinical dementia performed significantly
poorer than those with prodromal dementia on all out-
comes aside from verbal fluency, BRIEF-A total score
and Behavioral Regulation Index, and Developmental
NEuroPSYchological Assessment-II car and motorbike
score. The largest effect sizes were for memory
measures (object memory, OMQ, and DLD cognitive
scores) and short ABS total score, where group
accounted for more than 20% of variance in scores for
each outcome.3.3. Sensitivity of cognitive markers to APOE genotype
Based on preceding analyses, we identified PAL first trial
memory score and SRT latency SD as outcomes most sensi-
tive to early AD progression. We compared performance for
these outcomes between adults aged 361 years with geno-
type APOE ε3/ε3 and APOE ε3/ε4. Performance for both
outcomes was significantly poorer for adults with genotype
APOE ε3/ε4, with genotype accounting for approximately
8% of variance in scores (PAL: APOE ε3/ε3 M 5 5.12,
SD 5 5.42, n 5 84, APOE ε3/ε4 M 5 2.26, SD 5 5.18,
n 5 35, F(1,114) 5 9.08, P 5 .003, h2 5 0.074; SRT:
APOE ε3/ε3 M 5 579.42, SD 5 295.63, n 5 87, APOE
ε3/ε4 M 5 739.49, SD 5 290.28, n 5 32,
F(1,114) 5 9.85, P 5 .002, h2 5 0.080).3.4. Sample sizes for RCTs using cognitive markers
Using PAL first trial memory score as a primary outcome
measure for an RCT to delay early cognitive decline with
scores for adults aged 36–40 years without clinical dementia
and for those aged 41-45 years (M 5 10.63, SD 5 6.72,
n 5 19; and M 5 5.90, SD 5 5.97, n 5 21, respectively;
pooled SD 5 6.69), an RCT to delay decline in those aged
36–40 years would need 43 individuals per group to detect
a significant treatment effect with 90% power. Using a
more cautious group difference of 2.70, 130 individuals
per group would be required.
Based on short ABS total scores showing later significant
age-related decline, we used this as a primary outcome mea-
sure for an RCT to delay later cognitive decline. Using
scores for adults aged 46–50 years without clinical dementia
and for those aged 51–55 years (M 5 70.87, SD 5 23.03,
n 5 39; and M 5 54.64, SD 5 27.56, n 5 36, respectively;
pooled SD 5 26.43), an RCT to delay decline in those aged
46–50 years would need 56 individuals per group to detect a
significant treatment effect with 90% power. Using a more
cautious group difference of 10.41, 136 individuals per
group would be required.4. Discussion
We have investigated cross-sectional changes in cogni-
tive abilities associated with AD development in over 300
adults with DS. Memory and attention measures were
most sensitive to aging, with significantly poorer perfor-
mance starting in the early 40s. Similarly, performance for
memory and attention outcomes was most sensitive to pro-
gression from preclinical to prodromal dementia, whereas
performance for memory outcomes was most sensitive to
progression from prodromal to clinical dementia. Using out-
comes identified as sensitive to AD progression, we esti-
mated possessing an APOE ε4 allele accounted for
approximately 8% of variance in scores, and modest sample
Table 3
Summary heat map demonstrating age groups where scores are significantly poorer than those for adults aged 16-30 years
Domain Outcomes 36–40 years 41–45 years 46–50 years 51–55 years 56–60 years
IQ KBIT-2 verbal raw score ** *** ***
KBIT-2 nonverbal raw score *** *** ***
Memory PAL first trial memory score ** *** *** ***
PAL stages completed * *** *** ***
Orientation ** *** ***
Object memory immediate recall ** *** ***
Object memory delayed recall ** *** ***
DLD cognitive score *** *** ***
OMQ total score ** *** ***
Executive function IED stage 1 errors * *** *** ***
IED stages completed ** *** ***
Verbal fluency *** *** ***
Tower of London *** *** ***
BRIEF-A total score
BRIEF-A Behavioral Regulation Index
BRIEF-A Metacognition Index
Attention SRT total correct *** *** ***
SRT mean latency * * *** *** ***
SRT latency standard deviation ** *** *** ***
Motor Finger-nose pointing * *** *** ***
NEPSY-II train and car *** *** ***
NEPSY-II car and motorbike *** *** ***
Adaptive Short ABS total score ** *** ***
Short ABS personal self-sufficiency * *** ***
Short ABS community self-sufficiency ** ** ***
Short ABS personal-social responsibility ** **
DLD social score * *** ***
NOTE. *P ,.05, **P , .01, and ***P , .001. Results are obtained from post hoc comparisons of ANCOVA results comparing age groups and including
premorbid ID severity and multimorbidity as covariates.
Abbreviations: ABS, Adaptive Behavior Scale; BRIEF-A, Behavior Rating Inventory of Executive Function–Adult version; DLD, Dementia Questionnaire
for People with Learning Disabilities; ID, intellectural disability; IED, intra-/extra-dimensional set shift; KBIT-2, Kaufmann Brief Intelligence Test 2; NEPSY-
II, Developmental NEuroPSYchological Assessment-II; OMQ, Observer Memory Questionnaire; PAL, paired associates learning; SRT, simple reaction time.
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fect to delay cognitive decline in an RCT.4.1. Strengths and limitations
We report results from the largest study of cognitive
decline in DS worldwide, using deep cognitive phenotyp-
ing to understand progression associated with the devel-
opment of AD. A major strength of our study is that we
have recruited a large, diverse, community sample of
adults with DS, with various stages of AD-related decline.
Based on prevalence data from Wu and Morris [1], we
have recruited approximately one in 85 of all adults
with DS in England and Wales, suggesting our sample
is likely to be largely representative of adults with DS
in the UK. We used a validated, sensitive battery of
cognitive tests and took account of potentially confound-
ing vision and hearing difficulties.
We used a cross-sectional approach, with analyses based
on the strong rationale of AD neuropathology being increas-
ingly present in adults with DS with aging; nevertheless, our
results need to be confirmed with longitudinal assessments
as cross-sectional approaches are vulnerable to cohort ef-fects. However, we controlled for age where possible.
Furthermore, missing data from cognitive outcomes were
not missing at random; adults with clinical dementia were
more likely to have scores missing [8]. We reduced this lim-
itation through imputing scores for cognitive tests when
adults had not understood test instructions. In addition, while
we used a thorough approach to categorize individuals into
preclinical and prodromal dementia, the information used
relied on retrospective judgments of carers, which may be
subject to recall bias. Finally, there are no standardized
thresholds of preclinical and prodromal dementia in DS.
We adapted concepts from Dubois et al. [25], defining pre-
clinical dementia by the absence of clinical symptoms of
AD and the presence of AD biomarker changes. Owing to
the presence of amyloid neuropathology in all adults with
DS from the mid-30s [2,4] and the near universal
development of dementia [3], we considered all adults
with DS aged 361 years to be in at least a preclinical state,
and those showing symptoms of cognitive decline but not
reaching the threshold for dementia diagnosis to be in a pro-
dromal state. We were able to show clear cognitive differ-
ences between groups defined in this way, providing some
validation for our classification.
Table 4
Ages and scores for each outcome for adults aged 361 years split into preclinical, prodromal, and clinical dementia groups, with results of group comparisons for preclinical and prodromal dementia, and
prodromal and clinical dementia
Demographics and outcomes Preclinical dementia Prodromal dementia Clinical dementia
Preclinical dementia versus prodromal
dementia Prodromal dementia versus clinical dementia
Total number 68 46 56 N/A N/A
Number who failed hearing or vision test 4 (5.9%) 4 (8.7%) 6 (10.7%) N/A N/A
Age (years) 45.93 6 6.13 51.28 6 7.16 54.45 6 7.00 t(112) 5 4.27, P , .001 t(100) 5 2.25, P 5 .027
KBIT-2 verbal raw score 30.61 6 18.03 21.81 6 16.27 9.40 6 11.81 F(1,101) 5 1.20, P 5 .276, h2 5 0.012 F(1,87) 5 16.01, P , .001, h2 5 0.155
KBIT-2 nonverbal raw score 13.16 6 6.72 9.15 6 6.30 4.40 6 6.00 F(1,97) 5 1.86, P 5 .176, h2 5 0.019 F(1,83) 5 11.86, P 5 .001, h2 5 0.125
PAL first trial memory score 8.58 6 6.26 2.71 6 3.15 0.64 6 1.79 F(1,90) 5 13.90, P , .001, h2 5 0.134 F(1,78) 5 9.99, P 5 .002, h2 5 0.114
PAL stages completed 5.32 6 2.96 3.00 6 2.40 0.96 6 1.73 F(1,90) 5 7.15, P 5 .009, h2 5 0.074 F(1,78) 5 15.22, P , .001, h2 5 0.163
Orientation 8.98 6 4.04 6.15 6 4.31 2.78 6 3.84 F(1,96) 5 4.64, P 5 .034, h2 5 0.046 F(1,84) 5 14.30, P , .001, h2 5 0.145
Object memory immediate recall 8.92 6 4.05 6.64 6 4.12 2.24 6 3.64 F(1,94) 5 0.45, P 5 .505, h2 5 0.005 F(1,79) 5 22.94, P , .001, h2 5 0.225
Object memory delayed recall 4.93 6 2.29 3.82 6 2.33 1.31 6 2.03 F(1,94) 5 0.09, P 5 .763, h2 5 0.001 F(1,79) 5 23.44, P , .001, h2 5 0.229
DLD cognitive score* 8.73 6 10.04 16.47 6 10.20 28.31 6 10.65 F(1,92) 5 6.55, P 5 .012, h2 5 0.067 F(1,82) 5 25.87, P , .001, h2 5 0.240
OMQ total score* 73.84 6 17.21 92.97 6 16.60 117.74 6 12.73 F(1,94) 5 25.00, P , .001, h2 5 0.210 F(1,67) 5 44.52, P , .001, h2 5 0.399
IED stage 1 errors* 6.81 6 10.04 12.22 6 11.05 20.72 6 9.60 F(1,89) 5 2.75, P 5 .101, h2 5 0.030 F(1,79) 5 10.36, P 5 .002, h2 5 0.116
IED stages completed 5.75 6 3.24 3.84 6 3.52 1.26 6 2.61 F(1,89) 5 1.96, P 5 .165, h2 5 0.022 F(1,79) 5 12.02, P 5 .001, h2 5 0.132
Verbal fluency 9.38 6 6.40 4.75 6 4.35 2.54 6 3.96 F(1,96) 5 6.95, P 5 .010, h2 5 0.068 F(1,85) 5 4.42, P 5 .039, h2 5 0.049
Tower of London 6.72 6 3.39 3.78 6 3.51 1.42 6 2.92 F(1,97) 5 9.33, P 5 .003, h2 5 0.088 F(1,84) 5 10.36, P 5 .002, h2 5 0.110
BRIEF-A total score* 116.16 6 24.44 129.64 6 20.78 148.00 6 32.57 F(1,84) 5 6.82, P 5 .011, h2 5 0.075 F(1,61) 5 7.14, P 5 .010, h2 5 0.105
BRIEF-A Behavioral Regulation Index* 51.06 6 11.94 52.12 6 9.96 57.42 6 14.74 F(1,98) 5 0.19, P 5 .661, h2 5 0.002 F(1,72) 5 2.81, P 5 .098, h2 5 0.038
BRIEF-A Metacognition Index* 66.72 6 14.80 77.58 6 13.11 89.85 6 20.11 F(1,85) 5 12.99, P 5 .001, h2 5 0.133 F(1,61) 5 9.08, P 5 .004, h2 5 0.130
SRT total correct 83.11 6 28.56 66.22 6 31.37 34.29 6 31.03 F(1,87) 5 2.07, P 5 .154, h2 5 0.023 F(1,77) 5 17.09, P , .001, h2 5 0.182
SRT mean latency* 1015.60 6 669.55 1432.80 6 662.77 2082.42 6 636.40 F(1,87) 5 2.46, P 5 .121, h2 5 0.027 F(1,77) 5 16.41, P , .001, h2 5 0.176
SRT latency standard deviation* 438.94 6 267.64 674.31 6 211.57 839.48 6 216.29 F(1,87) 5 12.36, P 5 .001, h2 5 0.124 F(1,77) 5 8.37, P 5 .005, h2 5 0.098
Finger-nose pointing 8.25 6 5.27 6.32 6 5.21 2.60 6 4.33 F(1,95) 5 0.13, P 5 .725, h2 5 0.001 F(1,83) 5 10.97, P 5 .001, h2 5 0.117
NEPSY-II train and car 13.57 6 6.96 10.18 6 6.57 3.94 6 6.68 F(1,93) 5 0.25, P 5 .621, h2 5 0.003 F(1,82) 5 14.46, P , .001, h2 5 0.150
NEPSY-II car and motorbike 12.68 6 9.88 6.27 6 5.60 2.59 6 5.82 F(1,92) 5 3.98, P 5 .049, h2 5 0.041 F(1,81) 5 6.37, P 5 .014, h2 5 0.073
Short ABS total score 80.39 6 20.96 63.47 6 21.86 40.82 6 24.28 F(1,97) 5 5.52, P 5 .021, h2 5 0.054 F(1,84) 5 21.22, P , .001, h2 5 0.202
Short ABS personal self-sufficiency 28.40 6 4.84 25.10 6 6.99 16.33 6 9.65 F(1,100) 5 2.02, P 5 .159, h2 5 0.020 F(1,86) 5 18.01, P , .001, h2 5 0.173
Short ABS community self-sufficiency 28.97 6 11.62 20.24 6 10.51 11.55 6 9.16 F(1,99) 5 6.38, P 5 .013, h2 5 0.061 F(1,86) 5 18.47, P , .001, h2 5 0.177
Short ABS personal-social responsibility 23.02 6 6.40 18.90 6 6.44 12.94 6 7.21 F(1,100) 5 3.01, P 5 .086, h2 5 0.029 F(1,86) 5 19.78, P , .001, h2 5 0.187
DLD social score* 9.36 6 6.31 13.85 6 8.51 24.76 6 12.66 F(1,95) 5 4.04, P 5 .047, h2 5 0.041 F(1,83) 5 15.92, P , .001, h2 5 0.161
NOTE. Ages and scores given are mean 6 standard deviation. Group comparisons included age, premorbid ID severity, and multimorbidity as covariates.
Abbreviations: ABS, Adaptive Behavior Scale; BRIEF-A, Behavior Rating Inventory of Executive Function–Adult version; DLD, Dementia Questionnaire for Peoplewith Learning Disabilities; ID, intellectual
disability; IED, intra-/extra-dimensional set shift; KBIT-2, Kaufmann Brief Intelligence Test 2; NEPSY-II, Developmental NEuroPSYchological Assessment-II; OMQ, Observer Memory Questionnaire; PAL,
paired associates learning; SRT, simple reaction time.
*Higher scores represent poorer ability.
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Table 5
Summary heat map demonstrating effect sizes of group differences
comparing adults aged 361 years with preclinical and prodromal dementia,
and prodromal and clinical dementia
Domain Outcomes
Preclinical
versus
prodromal
Prodromal
versus
clinical
IQ KBIT-2 verbal raw score **
KBIT-2 nonverbal raw score *
Memory PAL first trial memory score * *
PAL stages completed **
Orientation *
Object memory immediate recall ***
Object memory delayed recall ***
DLD cognitive score ***
OMQ total score *** ***
Executive
function
IED stage 1 errors *
IED stages completed *
Verbal fluency
Tower of London *
BRIEF-A total score *
BRIEF-A Behavioral Regulation Index
BRIEF-A Metacognition Index * *
Attention SRT total correct **
SRT mean latency **
SRT latency standard deviation *
Motor Finger-nose pointing *
NEPSY-II train and car **
NEPSY-II car and motorbike
Adaptive Short ABS total score ***
Short ABS personal self-sufficiency **
Short ABS community
self-sufficiency
**
Short ABS personal-social
responsibility
**
DLD social score **
NOTE. *h2 . 0.10, yh2 . 0.15, and zh2 . 0.20. Group comparisons
included age, premorbid ID severity, and multimorbidity as covariates.
Abbreviations: ABS, Adaptive Behavior Scale; BRIEF-A, Behavior Rat-
ing Inventory of Executive Function–Adult version; DLD, Dementia Ques-
tionnaire for People with Learning Disabilities; ID, intellectual disability;
IED, intra-/extra-dimensional set shift; KBIT-2, Kaufmann Brief Intelli-
gence Test 2; OMQ, Observer Memory Questionnaire; NEPSY-II, Develop-
mental NEuroPSYchological Assessment-II; PAL, paired associates
learning; SRT, simple reaction time.
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with DS
Dementia diagnosis in people with DS may be compli-
cated by variable premorbid ID, in addition to health comor-
bidities including depression and hypothyroidism, which
may present with cognitive changes. Fully understanding
the time course of dementia development in DS is essential
for better detection and monitoring of cognitive decline, to
detect reliable biomarkers for the progression of decline,
and for the development of clinical trials. Previous studies
have also demonstrated poorer performance associated
with aging, cognitive decline, and dementia in adults with
DS for various tasks within our battery [23,28–32]. Study
results have however differed regarding the sequence of
cognitive changes. Similar to our results which suggestthat changes in memory and attention are the earliest
changes associated with dementia development, other
studies have reported memory decline as an early change
[33–35], with decline in memory [36,37] and attention
[38] preceding other changes by up to 3 years. In contrast,
a recent systematic review suggested executive dysfunction
with behavioral and personality changes, caused by early
frontal lobe involvement, may precede memory loss [39]
(also see [31,40,41]). Although these carer-reported changes
in behavior and personality are likely to occur relatively
early in the course of dementia in DS, it is possible that
carers observe such changes earlier than memory changes
that may be less obvious in those with more severe IDs
and with communication impairments. Differences in test
sensitivity may also explain conflicting results.
The earliest changes in both ADAD [6] and sporadic late-
onset AD are also memory changes, though a minority of
individuals may initially show an atypical cognitive presen-
tation, with behavioral change, language impairment, dys-
calculia, or dysexecutive syndrome [6]. The early memory
impairments in adults with DS support similar underlying
neurological changes in the development of dementia to
these other forms of AD and indicate the importance of
the population with DS for clinical trials of treatments to pre-
vent or modify AD.4.3. Implications for clinical trials
The recent failure of clinical drug trials directed at amy-
loid, including anti-amyloid antibodies and BACE inhibi-
tion, has been a considerable disappointment given the
genetic evidence suggesting reduced BACE cleavage over
a lifetime protects against AD [42]. The most prevalent
explanation for this failure is that treatments targeting amy-
loid may only be effective during the extended prodromal
phase of AD [43]. The predictable onset of pathology and
high incidence of dementia in DS suggest this is a key pop-
ulation for trials in the preclinical or prodromal stage of AD
to prevent or delay decline. To date, individuals with DS
have been excluded from such trials despite having the
most common genetic cause of AD and a considerable
burden of disease, in part due to the lack of reliable cognitive
outcome data.
Intervention studies to prevent or delay AD-related
decline in those with DS depend on determining the
optimal age for treatments to be given, outcome measures
that are most sensitive to decline, and relevant effect sizes
for such outcome measures to determine adequate sample
sizes. Our results address these uncertainties, and although
longitudinal studies are needed to confirm our findings,
they provide valuable data to plan trials to prevent or delay
decline. We found that changes in memory and attention,
specifically in the CANTAB PAL and SRT tests, are
most sensitive to AD progression. These tests have stan-
dardized computerized administrations and so would be
suitable measures for use in a multicentre clinical trial.
C.M. Startin et al. / Alzheimer’s & Dementia- (2018) 1-13 11RCTs would likely use several outcomes, both assessed
directly and via informant report (with the latter particu-
larly important for those with more severe ID [44]), and
our results offer a critical first step toward such trials.
We estimate modest samples will be sufficient to detect a
significant treatment effect to delay cognitive decline,
with treatment started in the mid-late 30s to delay early
decline (i.e., before the development of amyloid PET pa-
thology [45]) and started in the mid-late 40s to delay later
decline (i.e., before the majority of individuals receive a
clinical dementia diagnosis [3,46]). Accounting for the
effect of APOE ε4 in the trial design may further sharpen
effect sizes, as may accounting for amyloid or tau PET
pathology [47]. However, these calculations are based on
5-year age bands; a shorter time frame may require larger
sample sizes, while interim analyses may help to shorten
trial length. Furthermore, trial samples would need to be
larger at entry to account for dropout. Nevertheless, our
data and previous studies suggest that even when account-
ing for this, the number of individuals required for a pre-
ventative RCT would be feasible to recruit [48,49], and
such trials would likely also be informative for studies of
ADAD and sporadic late-onset AD.Acknowledgments
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1. Systematic review: A literature search of PubMed
identified 39 studies investigating cognitive changes
associated with Alzheimer’s disease and aging in
Down syndrome. Most studies were small with
mixed results, and few investigated prodromal
changes. Some identified early changes in memory,
and others suggested that changes in executive func-
tion and associated behavior occur first.
2. Interpretation: In the largest cross-sectional cogni-
tive phenotyping study to date of 312 adults with
Down syndrome, we found that tests of memory and
attention were most sensitive to decline from the
preclinical to prodromal dementia state. We used our
results to identify primary outcomes for randomized
controlled trials of treatments to delay cognitive
decline and to estimate sample sizes needed for
randomized controlled trials to detect significant
treatment effects.
3. Future directions: Given the high burden of dementia
in Down syndrome, the development of randomized
controlled trials to delay cognitive decline is essen-
tial, with our results offering a crucial first step to-
ward such trials.
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